|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's range||10.84 - 11.45|
|52-week range||4.41 - 21.70|
|Beta (5Y monthly)||1.25|
|PE ratio (TTM)||N/A|
|Earnings date||08 Nov 2023 - 13 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||27.83|
Shares of regenerative medicines maker Avita Medical (NASDAQ: RCEL) were down more than 27% as of 1 p.m. ET on Monday. The healthcare company released a Securities and Exchange Commission (SEC) filing on Monday detailing that the Food and Drug Administration (FDA) was asking for more information before granting the company's pre-market approval (PMA) supplement application to give Breakthrough Therapy designation to its Recell Go automated cell disaggregation device. Avita Medical submitted its PMA for Recell Go on June 30, and that set up the typical 180-day review cycle for the product.
Avita Medical Inc. (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Shares of Avita Medical (NASDAQ: RCEL) were up more than 16% early Thursday afternoon after the healthcare company got Food and Drug Administration (FDA) approval for a therapy to treat a skin disease. On Wednesday, after the markets closed, the company announced that the FDA approved Avita's supplement to use its Recell System to treat full-thickness skin defects, including wounds that stem from surgery or trauma. The approval was based on a clinical trial that the company completed in March.